RASSF10 suppresses hepatocellular carcinoma growth by activating P53 signaling and methylation of RASSF10 is a docetaxel resistant marker

Yongshuai Jin, Baoping Cao, Meiying Zhang, Qimin Zhan, James G. Herman, Miao Yu, Mingzhou Guo

Research output: Contribution to journalArticle

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignances and the second leading cause of cancer related death worldwide. RASSF10 is located on chromosome 11p15.2, a region that shows frequent loss of heterozygosity (LOH) in several cancer types. Our previous study found that RASSF10 suppresses colorectal cancer growth by activating P53 signaling. To explore the epigenetic changes and the mechanism of RASSF10 in human HCC, 69 cases of primary HCC, twenty cases of normal liver tissue samples and 17 HCC cell lines were involved in this study. We found that RASSF10 was methylated in 82.6% (57/69) of human primary HCC and methylation of RASSF10 was significantly associated with tumor size (P <0.05) and TNM stage (P <0.05). The expression of RASSF10 was regulated by promoter region methylation. Restoration of RASSF10 expression suppressed cell proliferation, induced apoptosis and G2/M phase arrest, as well as sensitized cells to docetaxel and activated P53 signaling in HepG2 and QGY7703 cells. In conclusion, we demonstrated that RASSF10 is frequently methylated in human HCC and its methylation is a potential docetaxel resistant marker. Our data also indicate that RASSF10 suppresses human HCC growth by activating P53 signaling.

Original languageEnglish (US)
Pages (from-to)231-240
Number of pages10
JournalGenes and Cancer
Volume6
Issue number5-6
StatePublished - 2015
Externally publishedYes

Fingerprint

docetaxel
Methylation
Hepatocellular Carcinoma
Growth
Neoplasms
Loss of Heterozygosity
G2 Phase
Hep G2 Cells
Genetic Promoter Regions
Epigenomics
Cell Division
Colorectal Neoplasms
Chromosomes

Keywords

  • DNA methylation
  • Epigenetics
  • Hepatocellular carcinoma
  • P53 signaling
  • RASSF10

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

RASSF10 suppresses hepatocellular carcinoma growth by activating P53 signaling and methylation of RASSF10 is a docetaxel resistant marker. / Jin, Yongshuai; Cao, Baoping; Zhang, Meiying; Zhan, Qimin; Herman, James G.; Yu, Miao; Guo, Mingzhou.

In: Genes and Cancer, Vol. 6, No. 5-6, 2015, p. 231-240.

Research output: Contribution to journalArticle

Jin, Y, Cao, B, Zhang, M, Zhan, Q, Herman, JG, Yu, M & Guo, M 2015, 'RASSF10 suppresses hepatocellular carcinoma growth by activating P53 signaling and methylation of RASSF10 is a docetaxel resistant marker', Genes and Cancer, vol. 6, no. 5-6, pp. 231-240.
Jin, Yongshuai ; Cao, Baoping ; Zhang, Meiying ; Zhan, Qimin ; Herman, James G. ; Yu, Miao ; Guo, Mingzhou. / RASSF10 suppresses hepatocellular carcinoma growth by activating P53 signaling and methylation of RASSF10 is a docetaxel resistant marker. In: Genes and Cancer. 2015 ; Vol. 6, No. 5-6. pp. 231-240.
@article{b42a4a77e8114b139d0f5d44ae32c8dc,
title = "RASSF10 suppresses hepatocellular carcinoma growth by activating P53 signaling and methylation of RASSF10 is a docetaxel resistant marker",
abstract = "Hepatocellular carcinoma (HCC) is one of the most common malignances and the second leading cause of cancer related death worldwide. RASSF10 is located on chromosome 11p15.2, a region that shows frequent loss of heterozygosity (LOH) in several cancer types. Our previous study found that RASSF10 suppresses colorectal cancer growth by activating P53 signaling. To explore the epigenetic changes and the mechanism of RASSF10 in human HCC, 69 cases of primary HCC, twenty cases of normal liver tissue samples and 17 HCC cell lines were involved in this study. We found that RASSF10 was methylated in 82.6{\%} (57/69) of human primary HCC and methylation of RASSF10 was significantly associated with tumor size (P <0.05) and TNM stage (P <0.05). The expression of RASSF10 was regulated by promoter region methylation. Restoration of RASSF10 expression suppressed cell proliferation, induced apoptosis and G2/M phase arrest, as well as sensitized cells to docetaxel and activated P53 signaling in HepG2 and QGY7703 cells. In conclusion, we demonstrated that RASSF10 is frequently methylated in human HCC and its methylation is a potential docetaxel resistant marker. Our data also indicate that RASSF10 suppresses human HCC growth by activating P53 signaling.",
keywords = "DNA methylation, Epigenetics, Hepatocellular carcinoma, P53 signaling, RASSF10",
author = "Yongshuai Jin and Baoping Cao and Meiying Zhang and Qimin Zhan and Herman, {James G.} and Miao Yu and Mingzhou Guo",
year = "2015",
language = "English (US)",
volume = "6",
pages = "231--240",
journal = "Genes and Cancer",
issn = "1947-6019",
publisher = "SAGE Publications Inc.",
number = "5-6",

}

TY - JOUR

T1 - RASSF10 suppresses hepatocellular carcinoma growth by activating P53 signaling and methylation of RASSF10 is a docetaxel resistant marker

AU - Jin, Yongshuai

AU - Cao, Baoping

AU - Zhang, Meiying

AU - Zhan, Qimin

AU - Herman, James G.

AU - Yu, Miao

AU - Guo, Mingzhou

PY - 2015

Y1 - 2015

N2 - Hepatocellular carcinoma (HCC) is one of the most common malignances and the second leading cause of cancer related death worldwide. RASSF10 is located on chromosome 11p15.2, a region that shows frequent loss of heterozygosity (LOH) in several cancer types. Our previous study found that RASSF10 suppresses colorectal cancer growth by activating P53 signaling. To explore the epigenetic changes and the mechanism of RASSF10 in human HCC, 69 cases of primary HCC, twenty cases of normal liver tissue samples and 17 HCC cell lines were involved in this study. We found that RASSF10 was methylated in 82.6% (57/69) of human primary HCC and methylation of RASSF10 was significantly associated with tumor size (P <0.05) and TNM stage (P <0.05). The expression of RASSF10 was regulated by promoter region methylation. Restoration of RASSF10 expression suppressed cell proliferation, induced apoptosis and G2/M phase arrest, as well as sensitized cells to docetaxel and activated P53 signaling in HepG2 and QGY7703 cells. In conclusion, we demonstrated that RASSF10 is frequently methylated in human HCC and its methylation is a potential docetaxel resistant marker. Our data also indicate that RASSF10 suppresses human HCC growth by activating P53 signaling.

AB - Hepatocellular carcinoma (HCC) is one of the most common malignances and the second leading cause of cancer related death worldwide. RASSF10 is located on chromosome 11p15.2, a region that shows frequent loss of heterozygosity (LOH) in several cancer types. Our previous study found that RASSF10 suppresses colorectal cancer growth by activating P53 signaling. To explore the epigenetic changes and the mechanism of RASSF10 in human HCC, 69 cases of primary HCC, twenty cases of normal liver tissue samples and 17 HCC cell lines were involved in this study. We found that RASSF10 was methylated in 82.6% (57/69) of human primary HCC and methylation of RASSF10 was significantly associated with tumor size (P <0.05) and TNM stage (P <0.05). The expression of RASSF10 was regulated by promoter region methylation. Restoration of RASSF10 expression suppressed cell proliferation, induced apoptosis and G2/M phase arrest, as well as sensitized cells to docetaxel and activated P53 signaling in HepG2 and QGY7703 cells. In conclusion, we demonstrated that RASSF10 is frequently methylated in human HCC and its methylation is a potential docetaxel resistant marker. Our data also indicate that RASSF10 suppresses human HCC growth by activating P53 signaling.

KW - DNA methylation

KW - Epigenetics

KW - Hepatocellular carcinoma

KW - P53 signaling

KW - RASSF10

UR - http://www.scopus.com/inward/record.url?scp=84949555472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949555472&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 231

EP - 240

JO - Genes and Cancer

JF - Genes and Cancer

SN - 1947-6019

IS - 5-6

ER -